Repligen (RGEN) Stock: Buy, Sell, or Hold?
RGEN - Repligen Corp
$165.18
0.50 (0.30%)
â˛
5d:
-2.61%
30d:
-0.31%
90d:
+23.89%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Oct 27, 2026
Get Alerted When RGEN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: RGEN is fairly priced but lacks strong directional signals. At 1.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: RGEN is fairly priced but lacks strong directional signals. At 1.7% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$129.01
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$80.10
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RGEN is currently trading at $165.18, which is considered slightly low relative to its 30-day fair value range of $161.82 to $178.11. The stock's valuation (Forward PE: 62.3) is in line with its historical norms (59.2). At these levels, the market is pricing in 1.7% annual earnings growth.
Technical Outlook: Technically, RGEN is in a strong uptrend. The price is currently testing key support at $161.14. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: RGEN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $189.48 (+14.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RGEN is in a strong uptrend. The price is currently testing key support at $161.14. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: RGEN scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $189.48 (+14.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$161.82 -
$178.11
Company Quality Score
45/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
58.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($189.48)
- BULLISH: Expecting earnings turnaround to 1.7% growth with 11.9% revenue growth
- WARNING: Composite score 45/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$161.82 -
$178.11
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$161.14
Resistance Level
$182.57
Current Trend
Strong Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
62.33
Wall Street Target
$189.48
(+14.7%)
Revenue Growth (YoY)
11.9%
Earnings Growth (YoY)
-65.9%
Profit Margin
5.3%
Valuation Premium vs History
+1.7% premium
PE vs Historical
62.3 vs 59.2
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+1.7%
(market-implied from PE analysis)
1-Year Target
$167.99
(+2%)
2-Year Target
$170.84
(+3%)
3-Year Target
$173.75
(+5%)
3-Yr Target (if PE normalizes)
(PE: 62â59)
PE COMPRESSION
$165.01
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 62.3, Growth: 28.4%)
$349.40
(+112%)
Base:
(SPY PE: 20.2, Growth: 28.4%)
$113.06
(-32%)
Bear:
(PE: 17.1, Growth: 28.4%)
$96.10
(-42%)
đ
Valuation based on Current Earnings
Forward PE: 60.24 | Forward EPS (Implied): $2.74
Bull Case
$199.45
(+21%)
Analyst growth 15.0%, PE expands to 63.3
Base Case
$165.18
(0%)
Market implied 0.0%, PE stable at 60.2
Bear Case
$126.36
(-24%)
Severe decline -15.0%, PE contracts to 54.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 12, 2026 1:43 PM ET
Data refreshes hourly during market hours. Next update: 2:43 PM
Data refreshes hourly during market hours. Next update: 2:43 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGEN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Instruments & Supplies Stocks
Top-rated stocks in Medical Instruments & Supplies by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ISRG
Intuitive Surgical Inc |
BUY
33 analysts |
$478 | 53 HOLD |
|
ALC
Alcon AG |
STRONG BUY
27 analysts |
$85 | 35 SELL |
|
WST
West Pharmaceutical ServâĻ |
STRONG BUY
13 analysts |
$405 | 63 BUY |
|
RMD
ResMed Inc |
BUY
19 analysts |
$246 | 41 HOLD |
|
COO
The Cooper Companies, Inc |
BUY
19 analysts |
$82 | 43 HOLD |
